CO-36 | PLATELETS MATTER: THROMBIN GENERATION IN PLATELET‐RICH-PLASMA VS. PLATELET‐POOR‐PLASMA UNDER NON-REPLACEMENT THERAPIES IN HEMOPHILIA
Background and Aims. Non-replacement therapies have transformed the management of Hemophilia A (HA) and B (HB). Emicizumab (Emz) is a recombinant bispecific monoclonal antibody that mimics activated FVIII (FVIIIa), restoring FX activation and thrombin generation. Concizumab (Concz) is an anti–tissue factor pathway inhi...